Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification

医学 转移 阶段(地层学) 外科肿瘤学 癌症 肿瘤科 内科学 切除术 化疗 普通外科 外科 生物 古生物学
作者
Kazuhiro Yoshida,Kazuya Yamaguchi,Naoki Okumura,Toshiyuki Tanahashi,Yasuhiro Kodera
出处
期刊:Gastric Cancer [Springer Nature]
卷期号:19 (2): 329-338 被引量:278
标识
DOI:10.1007/s10120-015-0575-z
摘要

Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors that were originally unresectable or marginally resectable for technical and/or oncological reasons. However, the indications for resection remain to be clarified. In the present review, we focus on the biology and heterogeneous characteristics of stage IV GC and propose new categories of classification. Stage IV GC patients can be divided based on the absence (categories 1 and 2) or presence (categories 3 and 4) of macroscopically detectable peritoneal dissemination, which has a different biological outcome compared to hematological metastasis. Category 1 is defined oncologically as stage IV but the metastasis is technically resectable. Category 2 includes a marginally resectable metastasis or patients for whom the operation would not necessarily be the best choice. Category 3 includes a potentially unresectable metastasis of peritoneal dissemination that is only macroscopically detectable. Category 4 includes noncurable metastasis with peritoneal and other organ metastasis. The indications for conversion therapy might include the patients from category 2, some patients from category 3 and a very small number of patients from category 4. The longer survival can be expected for patients corresponding to categories 1, 2 and, to a lesser extent, 3, while the treatment of other patients focuses on "care." The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Chris学长完成签到,获得积分10
刚刚
1秒前
1秒前
maplesirup完成签到,获得积分10
2秒前
赵维雪发布了新的文献求助10
2秒前
3秒前
kaunis关注了科研通微信公众号
3秒前
幕雪应助科研通管家采纳,获得10
3秒前
科目三应助科研通管家采纳,获得10
3秒前
星辰大海应助科研通管家采纳,获得10
3秒前
隐形曼青应助科研通管家采纳,获得10
3秒前
在水一方应助科研通管家采纳,获得10
3秒前
华仔应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
传奇3应助科研通管家采纳,获得10
4秒前
幕雪应助科研通管家采纳,获得10
4秒前
乐乐应助科研通管家采纳,获得10
4秒前
Hello应助tfq200采纳,获得10
4秒前
CodeCraft应助科研通管家采纳,获得10
4秒前
callmefather应助科研通管家采纳,获得10
4秒前
星辰大海应助科研通管家采纳,获得10
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
FashionBoy应助科研通管家采纳,获得10
4秒前
小二郎应助bai采纳,获得10
4秒前
Lucas应助科研通管家采纳,获得10
4秒前
汤雄文完成签到,获得积分10
5秒前
隐形曼青应助尹尹尹采纳,获得10
5秒前
6秒前
pluto应助雷打不动我雷哥采纳,获得10
6秒前
6秒前
高会和发布了新的文献求助10
6秒前
6秒前
7秒前
葳蕤发布了新的文献求助10
9秒前
Hello应助赵维雪采纳,获得10
9秒前
lili完成签到,获得积分10
9秒前
顺利毕业完成签到,获得积分10
9秒前
10秒前
10秒前
虚幻听安完成签到 ,获得积分10
11秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3233445
求助须知:如何正确求助?哪些是违规求助? 2879969
关于积分的说明 8213423
捐赠科研通 2547415
什么是DOI,文献DOI怎么找? 1376927
科研通“疑难数据库(出版商)”最低求助积分说明 647713
邀请新用户注册赠送积分活动 623150